Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Farmers Insurance
Daiichi Sankyo
Citi
Argus Health

Generated: July 24, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206977

Try a free trialSee Plans and Pricing

« Back to Dashboard

NDA 206977 describes TIROSINT-SOL, which is a drug marketed by Institut Biochimique and is included in one NDA. It is available from one supplier. Additional details are available on the TIROSINT-SOL profile page.

The generic ingredient in TIROSINT-SOL is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
Summary for 206977
Tradename:TIROSINT-SOL
Applicant:Institut Biochimique
Ingredient:levothyroxine sodium
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 206977
Suppliers and Packaging for NDA: 206977
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TIROSINT-SOL levothyroxine sodium SOLUTION;ORAL 206977 NDA IBSA Pharma Inc. 71858-0105 71858-0105-1 2 POUCH in 1 CARTON (71858-0105-1) > 5 AMPULE in 1 POUCH (71858-0105-4) > 1 mL in 1 AMPULE
TIROSINT-SOL levothyroxine sodium SOLUTION;ORAL 206977 NDA IBSA Pharma Inc. 71858-0105 71858-0105-5 6 POUCH in 1 CARTON (71858-0105-5) > 5 AMPULE in 1 POUCH (71858-0105-4) > 1 mL in 1 AMPULE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength13MCG/ML
Approval Date:Dec 15, 2016TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength25MCG/ML
Approval Date:Dec 15, 2016TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength50MCG/ML
Approval Date:Dec 15, 2016TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Daiichi Sankyo
Julphar
Cipla
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.